VentriPoint Diagnostics Ltd.
TSX VENTURE : VPT

VentriPoint Diagnostics Ltd.

May 17, 2011 11:17 ET

VentriPoint Diagnostics Ltd.: Distinctive Shapes Found in Right Hearts of Patients With Pulmonary Arterial Hypertension Can Be Characterized by 3D-Shape Analysis

SEATTLE, WASHINGTON--(Marketwire - May 17, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) is announcing the presentation at the Annual Congress of the American Thoracic Society on research conducted by P.J. Leary (University of Washington), C.E. Kurtz(University of Wisconsin), C.L. Hough (Harborview Medical Center/University of Washington), M.P. Waiss(VentriPoint) and F.H. Sheehan(University of Washington) showing 3D analysis is able to visualize and characterize distinctive shapes in the right heart of patients with pulmonary arterial hypertension (PAH) as compared to normal controls. Thisanalysis illustrates the importance of 3D shape analysis of the RV in PAH.

"The American Thoracic Society meeting is the largest gathering of pulmonary physicians in the world with 12,000 total attendees expected this year", said Dr. George Adams, President and CEO of VentriPoint, "A simple method to diagnosis and monitor people at risk for all forms of Pulmonary Hypertensionwould result in 10,000,000 cardiac scans annually in the United States, if current clinical guidelines were followed."

Dr. Leary will present the paper entitled "Three-Dimensional Echocardiographic Characterization of the Right Ventricle In Pulmonary Hypertension" on Tuesday, May 17 in Exhibit Hall B, Area H in the Colorado Convention Center.

About Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) is the most serious form of the five recognized groups of pulmonary hypertension. PAH is a devastating disease with an average lifespan of less than 3 years after diagnosis if untreated. It affects individuals of all ages from infancy to the elderly. Although treatment started early after detection appears more effective than when started later, the majority of patients with PAH are diagnosed late. PAH can occur for no known reasons but also occurs in association with many common conditions such aschronic liver disease and liver cirrhosis; rheumatic disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and recommendations to start treatment early, tests enabling detection as early as possible should prove invaluable.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and it is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information